Evotec SE: Positive Phase IIb Data for Investigational P2X3 Antagonist in Patients with Refractory Chronic Cough

·1 min read

HAMBURG, GERMANY / ACCESSWIRE / August 3, 2021 / Evotec SE (Frankfurt Stock Exchange, MDAX/TecDAX, ISIN: DE 000 566480 9, WKN 566480) announces that the Company has been informed by Bayer about positive Phase IIb results from a clinical trial evaluating the efficacy and safety of the investigational P2X3 receptor antagonist eliapixant (BAY1817080) in patients with refractory chronic cough. The underlying molecule is a P2X3 receptor antagonist in Bayer's clinical development pipeline originating from a former Evotec/Bayer multi-target research alliance. The primary efficacy outcome was met showing a statistically significant improvement in 24-hour cough counts per hour (average hourly cough frequency based on 24-hour sound recordings) over placebo after 12 weeks of treatment. The data showed a favourable safety and tolerability profile.

Under the agreement from 2012, Evotec would be entitled to its next financial milestone payment upon start of a Phase III clinical study, to be decided by Bayer.

More details of the study will be presented by Bayer.

Contact:

Dr Werner Lanthaler
Chief Executive Officer
Evotec SE
Manfred Eigen Campus
Essener Bogen 7, 22419
Hamburg, Germany
Phone: +49.(0)40.560 81-242
werner.lanthaler@evotec.com

SOURCE: Evotec SE



View source version on accesswire.com:
https://www.accesswire.com/658139/Evotec-SE-Positive-Phase-IIb-Data-for-Investigational-P2X3-Antagonist-in-Patients-with-Refractory-Chronic-Cough

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting